Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
| ▸ | MELK | Q14680 | 1/20 | 0.47 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22094664 | 1.00 | CHEK1 (0.51) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL23137414 | 0.81 | CHEK1 (0.49) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL29701184 | 0.81 | CHEK1 (0.45) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL24803891 | 0.81 | CHEK1 (0.45) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL24338048 | 0.77 | CHEK1 (0.45) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL23178978 | 0.77 | CHEK1 (0.45) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL23556109 | 0.77 | CHEK1 (0.45) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL6798992 | 0.76 | JAK2 (0.61) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL28910254 | 0.73 | — | — | |
| SCHEMBL26705390 | 0.72 | GPR84 (0.38) | TNFRIPK1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024663-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2025024663-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-113923988-B | Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | CHEK1 1485/4885JAK2 1422/4885RPS6KA3 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.